Drugs / FG-3246
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06842498 | Feb 2026 → Mar 2028 expected | castration-resistant prostate carcinoma | Kyntra Bio | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FG-3246 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06842498 ↗ |
| Modality | Other / unclassified | “a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC)” NCT06842498 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” NCT06842498 ↗ |
| Target | CD46 | “a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC)” NCT06842498 ↗ |